CABALETTA BIO, INC. (CABA) News
Filter CABA News Items
CABA News Results
|Loading, please wait...|
CABA News Highlights
- For CABA, its 30 day story count is now at 4.
- Over the past 24 days, the trend for CABA's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about CABA are BIO, CELL and TOP.
Latest CABA News From Around the Web
Below are the latest news stories about CABALETTA BIO INC that investors may wish to consider to help them evaluate CABA as an investment opportunity.
Cabaletta Bio, Inc. (CABA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
PHILADELPHIA, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that the Company will participate in two upcoming investor conferences in September: Jefferies Cell & Genetic Medicine Summit: Steven Nichtberger, M.D., Chief Executive Officer, will participate in a fireside chat on Tuesday, September 26, 20
Top growth stocks for September include Cabaletta Bio Inc., Reata Pharmaceuticals Inc., and MoonLake Immunotherapeutics.
Cabaletta Bio, Reata Pharmaceuticals, and MoonLake Immunotherapeutics provided the best 1-year total returns as of mid-August.
These momentum stock picks are on a run, but it isn't too late to ride the rollercoaster amid broad market volatility.
The consensus price target hints at a 41.6% upside potential for Cabaletta Bio, Inc. (CABA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
PHILADELPHIA, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that the Company will participate in four upcoming investor conferences in September: 2023 Wells Fargo Healthcare Conference: Members of management will be available for one-on-one meetings on Wednesday, September 6, 2023 in Boston, MA.Citi’s
This week's Lab Notes has items on a gastric cancer discovery, a bio-manufacturing deal, a positive update on an experimental cancer therapy and more.
If you are looking for stocks that are well positioned to maintain their recent uptrend, Cabaletta Bio, Inc. (CABA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Cabaletta Bio and WuXi Advanced Therapies Announce Expansion of GMP Manufacturing Agreement to Include CABA-201
– Agreement expansion facilitates preparation for commercial readiness for CABA-201, enabling treatment of patients in multiple planned clinical trials with separate parallel cohorts – – Partnership for CABA-201 builds on existing manufacturing agreement for clinical trial supply of MuSK-CAART for MusCAARTes™ trial – PHILADELPHIA, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative tar